Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EKZ-102
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Financing
Eikonizo, Novo Nordisk Collaborate on EKZ-102 for Clinical Development
Details : The funding will be supporting the development of Eikonizo’s lead candidate, EKZ-102, a potential first-in-class, oral, CNS-penetrant, highly selective histone deacetylase 6 (HDAC6) inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 10, 2024
Lead Product(s) : EKZ-102
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Novo Nordisk
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, MSRD and Eikonizo will collaborate to advance Eikonizo’s HDAC6 inhibitors through preclinical and Phase 1b clinical studies respectively, with the opportunity to expand the collaboration after those studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Collaboration